Creative Biolabs Launches Advanced Neuroscience Platforms to Address Growing Neurodegenerative Disease Research Needs

Creative Biolabs has unveiled a suite of advanced neuroscience platforms designed to accelerate research into neurodegenerative diseases, particularly Alzheimer's disease, which affects millions worldwide. The World Health Organization reports more than 55 million people currently live with dementia globally, with Alzheimer's disease accounting for up to 70% of dementia cases.

The company's new Schwann Cell Assay platform focuses on the peripheral nervous system, enabling researchers to isolate Schwann cells from human, mouse, and rat species. This platform supports a co-culture system with neurons, allowing scientists to assess critical functional measures including neurotrophic factor secretion and myelination potential, both essential for regenerative medicine applications.

For central nervous system research, Creative Biolabs introduced its microglia phagocytosis assay service, which utilizes live-cell imaging and fluorescently labeled bioparticles. This technology enables researchers to visualize microglial phagocytic function in real time, providing valuable insights into neuroinflammation responses and pathological protein aggregate clearance.

The company has also developed comprehensive preclinical assessment services for Alzheimer's disease models, offering both 2D and 3D platforms that replicate key disease aspects including amyloid deposition, tauopathy, and neuroinflammation. These models can represent both familial and sporadic forms of Alzheimer's disease, originating from patient-derived induced pluripotent stem cells (iPSCs), creating more rigorous contexts for drug screening and mechanistic studies.

An upcoming webinar on the role of microglia in Alzheimer's disease is scheduled for September 18, 2025, at 10:00 AM EDT. Researchers interested in learning more about these advanced neuroscience tools can visit https://neuros.creative-biolabs.com/ for detailed information about the company's comprehensive neuroscience solutions.

These developments come at a critical time when the global research community faces increasing pressure to develop effective treatments for neurodegenerative diseases. The new platforms provide researchers with sophisticated tools to study complex neurological mechanisms, potentially accelerating the discovery of new therapeutic approaches for conditions affecting millions of patients worldwide.